Literature DB >> 2271781

Sensorineural hearing loss associated with vincristine treatment.

G Lugassy1, A Shapira.   

Abstract

We describe a 64-year-old patient with multiple myeloma who developed a sudden sensorineural hearing loss shortly after receiving chemotherapy with vincristine. Ototoxicity is not a known side effect of this drug. It would be of interest to perform repeated audiograms on patients receiving vincristine, in order to appreciate the actual ototoxicity of this drug.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2271781     DOI： 10.1007/bf01732887

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  6 in total

1.  [Recurrent paralysis induced by vincristine during the treatment of Hodgkin's disease].

Authors:  B Chauffert; B Lorcerie; F André; J F Besancenot; F Martin
Journal:  Presse Med       Date:  1989-11-25       Impact factor: 1.228

Review 2.  Neurotoxicity of commonly used antineoplastic agents (second of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-18       Impact factor: 91.245

Review 3.  Vincristine neurotoxicity.

Authors:  S Rosenthal; S Kaufman
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

4.  Vincristine-induced neuropathy. A clinical study of fifty leukemic patients.

Authors:  S G Sandler; W Tobin; E S Henderson
Journal:  Neurology       Date:  1969-04       Impact factor: 9.910

Review 5.  Vincristine neurotoxicity. Pathophysiology and management.

Authors:  S S Legha
Journal:  Med Toxicol       Date:  1986 Nov-Dec

6.  Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy.

Authors:  H E Hirvonen; T T Salmi; E Heinonen; K J Antila; I A Välimäki
Journal:  Cancer       Date:  1989-08-15       Impact factor: 6.860
  6 in total
  7 in total

Review 1.  Drug-induced tinnitus and other hearing disorders.

Authors:  H Seligmann; L Podoshin; J Ben-David; M Fradis; M Goldsher
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Hair cell toxicity in anti-cancer drugs: evaluating an anti-cancer drug library for independent and synergistic toxic effects on hair cells using the zebrafish lateral line.

Authors:  Yoshinobu Hirose; Julian A Simon; Henry C Ou
Journal:  J Assoc Res Otolaryngol       Date:  2011-07-06

3.  Long-term effects of vincristine on the peripheral nervous system.

Authors:  T J Postma; B A Benard; P C Huijgens; G J Ossenkoppele; J J Heimans
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

Review 4.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Chemotherapy-induced polyneuropathy. Part I. Pathophysiology.

Authors:  Krzysztof Brzeziński
Journal:  Contemp Oncol (Pozn)       Date:  2012-02-29

6.  Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.

Authors:  Diana J Moke; Chunqiao Luo; Joshua Millstein; Kristin R Knight; Shahrad R Rassekh; Beth Brooks; Colin J D Ross; Michael Wright; Victoria Mena; Teresa Rushing; Adam J Esbenshade; Bruce C Carleton; Etan Orgel
Journal:  Lancet Child Adolesc Health       Date:  2021-02-12

7.  Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Authors:  K Pussegoda; C J Ross; H Visscher; M Yazdanpanah; B Brooks; S R Rassekh; Y F Zada; M-P Dubé; B C Carleton; M R Hayden
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.